References
Cohen JI. A new vaccine to prevent herpes zoster. N Engl J Med. 2015;372(22):2149–50.
Hochauf K, Bandt D, Pöhlmann C, Monecke S, Toma M, Trautmann S. Fatal varicella zoster virus infection as first manifestation of idiopathic CD4+ T-cell lymphocytopenia. Eur J Clin Microbiol Infect Dis. 2005;24(10):706–8.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016;375(11):1019–32.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000.
Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014;32(30):3725–31.
Martire B, Azzari C, Badolato R, Canessa C, Cirillo E, Gallo V, et al. Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET). Vaccine. 2018;36(24):3541–54.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception, writing, and revision.
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cortesi, M., Badolato, R. Alternative Approach to Varicella Zoster Virus Prevention in a Child with Lymphopenia . J Clin Immunol 41, 1681–1682 (2021). https://doi.org/10.1007/s10875-021-01091-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-021-01091-7